HIV INFECTIONS

This study tested two different schedules of an experimental HIV vaccine in 147 healthy adults to see which one triggers a stronger immune response. Volunteers received either three doses of a DNA vaccine followed by one booster, or two doses of DNA followed by two boosters. The …

This study tested a vaccine called Triplex in 94 adults who have both HIV and cytomegalovirus (CMV). The goal was to see if the vaccine is safe and helps the immune system fight CMV better. Participants received two shots of either the vaccine or a placebo, and researchers monito…

This study tested a new HIV vaccine in 38 healthy infants who were exposed to HIV at birth but not infected. The goal was to see if the vaccine is safe and helps the body build defenses against HIV. Researchers measured side effects and immune responses after several doses.

This study tested whether an experimental HIV vaccine could prevent infection in over 5,400 sexually active adults in South Africa. Participants received either the vaccine or a placebo and were followed for up to 36 months. Unfortunately, the vaccine did not provide enough prote…

This early-stage study tested a new HIV vaccine in 51 healthy adults. The goal was to see if the vaccine is safe and if it triggers an immune response. Researchers tried different combinations of vaccine and adjuvants (ingredients that boost the immune system) to find the best ap…

This early-stage trial tested a new HIV vaccine in 24 healthy adults to see if it is safe and triggers an immune response. The vaccine uses a liposome (a tiny fat bubble) to deliver a piece of the HIV virus. The study found no major safety concerns and measured the body's antibod…

This study tested an experimental HIV vaccine called Trimer 4571 in 32 adults with HIV who were already on suppressive antiretroviral therapy (ART). The main goals were to see if the vaccine is safe and well tolerated, and whether it can help the immune system produce broadly neu…

This study tested an experimental HIV vaccine in 127 healthy, HIV-negative adults to see if it was safe and could trigger an immune response. Participants received different combinations of the vaccine with adjuvants (ingredients that boost the immune system). The main goal was t…

This early-stage study tested whether two experimental HIV vaccines (EnvSeq-1 and CH505 M5 gp120) are safe and can trigger an immune response. A total of 117 healthy, HIV-negative adults received the vaccines along with an adjuvant to boost immunity. The main goal was to check fo…

This early-stage study tested a new type of HIV vaccine in 46 healthy adults without HIV. The vaccine uses synthetic DNA to train the immune system, with some participants also receiving a protein boost. The main goal was to check safety and see if the vaccine triggers a strong i…

This study tested the Moderna COVID-19 mRNA vaccine in over 14,000 people living with HIV or other conditions that raise the risk of severe COVID-19. Researchers compared different vaccine schedules to see which best prevents COVID-19. The goal was to find the most effective way …

This study tested three different ways to give the hepatitis B vaccine to people with HIV. The goal was to find a method that works better than the standard shot, since HIV can weaken the immune response to vaccines. Over 400 adults with HIV and CD4 counts above 200 took part. Re…

This early-stage study tested two experimental HIV vaccines in 34 healthy, HIV-negative adults to see if they are safe and trigger an immune response. The vaccines use a harmless chimpanzee virus to deliver HIV proteins, followed by a protein boost. The goal is to gather safety d…

This study tested an experimental HIV vaccine in 132 healthy adults to see if it is safe and triggers an immune response. Participants received different combinations of the vaccine with or without adjuvants (substances that boost the immune response). The main goals were to chec…

This study tested whether people with well-controlled HIV could take their antiretroviral medication only 4 days in a row each week instead of every day. 640 adults with stable HIV and undetectable viral load for at least a year participated. After 48 weeks, the 4-day schedule wo…

This study tested a vaccine made from each patient's own immune cells and their own HIV virus. The goal was to see if it was safe and could lower the amount of virus in the blood after a break from standard HIV medication. Eleven HIV-positive adults who had never taken HIV drugs …

This study tested a new type of HIV vaccine made from a person's own white blood cells. It included 40 adults with HIV who were already on effective antiretroviral therapy (ART). The goal was to see if the vaccine is safe and can boost the body's immune response against HIV, pote…

This study tested an experimental oral drug called selgantolimod in 29 adults who have both chronic hepatitis B and HIV and have been on stable antiviral therapy for at least 5 years. The goal was to see if the drug is safe and can reduce hepatitis B surface antigen (HBsAg) level…

This study looked back at medical records of 800 adults with HIV to compare two drug combinations: a two-drug regimen (DTG/3TC) and a three-drug regimen (BIC/F/TAF). The goal was to see how well each kept the virus under control over 48 weeks. The study took place in multiple cli…

This study tested two statins, rosuvastatin and pravastatin, to see which is safer and more effective at lowering cholesterol in people with HIV who are on antiretroviral therapy. 86 participants with high cholesterol took one of the two drugs for 45 days. The goal was to manage …

This study tested a special wellness program designed to help veterans living with HIV quit smoking. 234 veterans who smoked at least 5 cigarettes a day took part. The program was compared to standard care, which included a quitline and text messaging support. The goal was to see…

This study looked at whether people with HIV who were already well-controlled on a regimen including enfuvirtide (an injectable drug) could safely switch to raltegravir (a pill). 170 participants were randomly assigned to either stay on enfuvirtide or switch to raltegravir. The m…

This study tested two versions of the H1N1 flu vaccine in 306 people with HIV to see which was safer and more effective. One vaccine included an immune booster (adjuvant), the other did not. The goal was to find the best way to protect this vulnerable group from the flu.

This study tested a single daily pill containing four HIV medicines in 129 teens and children with HIV. The goal was to see how the drug moves through the body, check safety, and confirm the right dose. Participants were either new to treatment or already had the virus under cont…

This study tested a new way to help people with two or more long-term health problems like HIV, high blood pressure, diabetes, asthma, or depression. Over 1,800 adults aged 40 and older in South Africa took part. Some clinics used a special decision-support tool and home visits f…

This study tested a new approach to help people with substance use disorders take their daily HIV prevention pill (PrEP) consistently. Participants used a digital pill that sends a signal to a smartphone app when swallowed, allowing researchers to track adherence in real time. Th…

This study tested a data-to-care approach to find and reconnect people living with HIV in Ukraine who had fallen out of care. Researchers used health records to identify 160 participants and then helped them get back into medical visits and start or restart HIV medication. The go…

This study tested whether alendronate, a drug used for osteoporosis, can improve bone density in people with HIV who also have weak bones. About 140 participants received either alendronate or a placebo for two years, along with calcium and vitamin D. The main goal was to measure…

This early-stage study tested a lab-made antibody called VRC01 in 24 adults with very recent HIV infection. The goal was to see if the antibody is safe and can lower the amount of virus in the blood, either alone or with standard HIV medicines. While the antibody was generally sa…

This study tested whether adding a powerful HIV drug called enfuvirtide (FUZEON®) to standard antiretroviral therapy could help people with HIV who also have a rare brain infection called progressive multifocal leukoencephalopathy (PML). PML is caused by the JC virus and typicall…

This study gave children and teens with HIV continued access to the drug dolutegravir after they finished earlier clinical trials. About 100 participants who were already doing well on the medication received it every 12 weeks until local approved versions became available. The g…

This study tested whether a mobile health unit could help people who inject drugs get treatment for opioid use disorder and HIV prevention or treatment all in one place. 447 adults with opioid use disorder joined the study. The goal was to see if this approach increased the use o…

This study tested two methods for offering HIV, hepatitis C, and addiction medications to 100 people who inject drugs. Participants received either standard care or a tele-harm reduction approach to start treatment quickly. The goal was to see which method helped more people achi…

This study looked at whether adults aged 50 and older with HIV could safely switch from a three-drug pill to a two-drug pill (DTG/3TC) while keeping the virus under control. About 200 participants who already had undetectable virus levels made the switch. The main goal was to see…

This study tested a once-daily HIV medication (tenofovir-emtricitabine plus efavirenz) in 70 adults with both HIV and tuberculosis. The goal was to see if a simpler, once-daily pill routine could effectively control HIV while being safe for people also being treated for TB. The m…

This study looked at how HIV drugs behave in the body of people starting treatment for the first time. 35 participants took a once-daily combination of atazanavir, ritonavir, tenofovir, and emtricitabine. A special electronic pill bottle (MEMS) recorded when they took their medic…

This study tested a new way to manage both HIV and high blood pressure together in Botswana. Over 4,600 adults with HIV and high blood pressure took part. The goal was to see if combining care helps more people get their blood pressure under control. If it works, this approach co…

This study looked at whether people with HIV who have high immune cell counts can safely take their medication in 6-month cycles instead of every day. 45 adults who had never taken HIV drugs before were given treatment for 6 months, then stopped for 6 months, and repeated this pa…

This study tested a new combination pill (polypill) that packs four heart failure medications into one tablet. The goal was to see if it helps people take their medicine more regularly compared to taking several separate pills. The study included 35 adults with heart failure and …

This study tested a once-daily pill containing two HIV drugs (dolutegravir and lamivudine) in 32 teens aged 12 to 18 who had never taken HIV medication before. The goal was to see if this simpler two-drug regimen could safely control the virus after 48 weeks. Results showed the p…

This study tested an enhanced football-based program for over 2,000 teenage girls in Zambia. The program added HIV self-testing, birth control information, and access to a nurse to the usual soccer activities. The goal was to see if this would increase HIV testing and use of cont…

This study tested a new experimental drug called VH4524184 for HIV in 84 healthy adults. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked at whether the drug affects certain liver enzymes. This is an early-stage trial, so it does…

This study looked at 558 people with HIV whose first treatment stopped working. It compared two different drug combinations to see which one controlled the virus better after 48 weeks. The goal was to find a safe and effective second-line option.

This study tested whether adding an extra drug, enfuvirtide, to standard HIV therapy for 6 months could help severely ill patients recover their immune systems faster. It included 195 adults with HIV who had very low CD4 counts or a recent AIDS diagnosis and had never taken HIV d…

This study tested a program where Black and Hispanic young adults (ages 18-29) with HIV used video calls to talk with trained peer health coaches. The goal was to help them stick to their HIV medication and lower their viral load. The program included eight weekly sessions focuse…

This study looked at whether people with HIV can donate a kidney to others with HIV. Only 3 donors took part, and researchers tracked their safety and kidney health over time. The goal was to see if this could be a safe way to get more kidneys for HIV+ patients in need.

This study tested a combination of two drugs, peginterferon alfa-2a and ribavirin, as a second-line treatment for chronic hepatitis C in 17 people with HIV who had not responded to their first hepatitis C treatment. The goal was to see if this approach could clear the hepatitis C…

This study tested two experimental oral medications (VH4004280 and VH4011499) in 44 adults with HIV who had never taken HIV drugs before. The goal was to see how well these drugs lower the amount of virus in the blood over 10 days. The study also checked for side effects. These d…

This study looked at how safe and effective a hepatitis A vaccine is for people with HIV, aged 1 to 50. About 392 participants received two vaccine doses six months apart. Researchers measured antibody levels and tracked side effects for one month after each dose to see if the va…

This study tested two different two-drug combinations in 61 adults with HIV who had not taken protease inhibitors before. The goal was to see if these combos could lower the virus to undetectable levels after 16 weeks. Researchers also watched for side effects and changes in body…

This study tested two long-acting injectable HIV medications (cabotegravir and rilpivirine) in 168 children and teens whose HIV was already under control. The goal was to find the right doses and see if the shots were safe and acceptable. Participants received oral pills first, t…

This study tested a counseling program for couples in Zambia where the woman is pregnant and living with HIV. The goal was to help women stay on their HIV medication and keep the virus under control. 478 couples took part, and the program focused on strengthening the relationship…

This study tested a drug called alirocumab in 118 people with HIV who were at risk for heart disease. The drug aims to lower cholesterol and reduce inflammation in the arteries, which can lead to heart attacks. Participants received either the drug or a placebo for about a year, …

This study tested a new type of counseling called BAPS to help smokers with HIV quit smoking. 651 participants were split into two groups: one received standard smoking cessation counseling, and the other received BAPS therapy. The goal was to see which approach led to more peopl…

This study looked at whether adding small rewards to integrated care centers helps people who inject drugs and men who have sex with men in India stay on HIV treatment and achieve viral suppression. Over 2,300 HIV-positive adults took part. The goal was to see which approach work…

This early-stage study tested a single injection of a new drug, lipovirtide, in 46 HIV-positive adults who had never taken antiviral medication. The main goal was to see if the drug is safe and how the body processes it. This is a first step in developing a potential new treatmen…

This study looked at whether adding a drug called Interleukin-2 (IL-2) to standard HIV treatment could help patients whose current therapy was failing and who had very low CD4 counts (below 200). The goal was to see if more patients could raise their CD4 counts above 200 after 52…

This early-stage study tested a new injectable drug, Lipovirtide, in 24 adults with HIV who were not taking any other HIV medications. The main goal was to check if the drug is safe and tolerable. Researchers also looked at how the drug works in the body and whether it can lower …

This study tested whether giving interleukin-2 (IL-2) injections to HIV patients who had never taken antiretroviral drugs could help keep their CD4 cell counts high and delay the need for standard HIV therapy. The trial enrolled 130 adults with CD4 counts between 300 and 500. Res…

This study looked at 66 HIV-positive adults who switched from a standard three-drug treatment to either a two-drug or a three-drug regimen. The goal was to see how these changes affected markers of inflammation and immune system balance. All participants had undetectable virus le…

This study tested whether HIV patients with long-term viral suppression could switch to a single drug (darunavir/r) instead of the standard two-drug regimen. 225 participants were followed for 48 weeks to see if the single drug could keep the virus undetectable. The goal was to s…

This study tested whether adding the drug maraviroc to standard HIV treatment for 24 weeks could improve immune function in people whose CD4 counts stayed low even though their HIV was well-controlled. The trial included 60 HIV-positive adults with CD4 counts below 350 and little…

This study tested a fast, simple test that checks for both HIV and syphilis at the same time in pregnant women in Guatemala. The goal was to see if using this test would help more women get screened and treated during pregnancy, which can prevent passing these infections to their…

This study looked at new, fast HIV tests that give results during a single clinic visit. The goal was to see if these tests help more people get linked to HIV treatment or prevention right away. Over 200 adults at high risk for HIV in Baltimore took part. The results showed that …

This study tested a strategy of using rapid point-of-care tests to screen pregnant women for sexually transmitted infections (STIs) like chlamydia, gonorrhea, and syphilis during routine antenatal visits in Zimbabwe. Over 1,000 women participated to see if immediate testing and t…

This study tested whether a smartphone app (GeoPassport) plus incentives and peer mentors could help men who have sex with men and transgender women leaving jail get HIV prevention services like PrEP and testing. 233 participants were split into two groups: one got routine case m…

This study tested a new way to help Latino men who have sex with men start taking PrEP, a daily pill that prevents HIV. Researchers trained siblings to talk to their brothers about PrEP. The goal was to see if this approach would increase the number of men who start using PrEP co…

This study tested a digital health program for male couples to help them create personalized HIV and STI prevention plans and agreements. 778 couples joined, and researchers tracked changes in infection rates, communication, and commitment over 16 months. The goal was to see if a…

This study tested a filmed soap opera (telenovela) designed to help Latinas learn about HIV prevention. About 95 women in North Carolina watched the episodes online. Researchers measured changes in condom use, HIV testing, and awareness of PrEP (a prevention pill) over several mo…

This project aimed to make it easier for young women in Kenya to get HIV prevention services, including PrEP pills, when they visit family planning clinics. Over 25,000 women took part. The goal was to see if offering HIV risk screening and PrEP at these clinics would help more w…

This study tested a program that helps people who use drugs prevent both HIV and overdose. It offered drug-checking services to understand what's in street drugs, along with HIV prevention medication (PrEP) for those who are HIV-negative. The goal was to see if this combined appr…

This study looked at two different strategies for giving cabotegravir, a long-acting HIV prevention shot, to HIV-negative men who have sex with men and transgender men in U.S. clinics. About 287 participants received the shot either after a month of pills or directly as injection…

This study tested the safety and drug levels of a daily HIV prevention pill (TAF-FTC) in 54 healthy Kenyan women. Participants took different numbers of doses per week to mimic real-world use. The goal was to find out how much drug is needed to prevent HIV and help interpret resu…

This study tested a program where trained peer navigators helped women involved in the criminal justice system access HIV prevention medication (PrEP). The goal was to reduce stigma and improve health. Thirty women at risk for HIV participated, and the program focused on linking …

This study looked at whether barbershops can be a good place to offer HIV prevention services to heterosexual men in the Kalangala Islands of Uganda. About 250 men took part to see if this approach is practical and well-liked. The goal was to find new ways to reach men who are at…

This study involved 209 men who have sex with men and transgender individuals who agreed to STI testing through a community app or in-person outreach. Researchers wanted to see how many would accept PrEP, a daily pill that prevents HIV, after being offered it. The goal was to und…

This large study tested whether an injectable drug called cabotegravir, given every 2 months, could prevent HIV better than taking a daily pill. It involved over 4,500 HIV-negative men and transgender women who have sex with men and are at high risk for HIV. The goal was to see i…

This study tested a program called Malkia Klabu ("Queen Club") in Tanzania. It made local drug shops more welcoming for adolescent girls and young women, so they could easily get HIV prevention services and contraception. The goal was to see if this approach increases HIV testing…

This study tested different ways to deliver HIV testing and counseling to young male couples (ages 15-24) to help them communicate better and reduce risky behaviors. Researchers compared how well each method worked at lowering condomless sex with casual partners and improving com…

This study tested a vaginal ring that slowly releases the HIV drug tenofovir over 90 days. 49 women participated to see how safe the ring is and how much drug gets into the body. The goal is to find a convenient way for women to protect themselves from HIV.

This study tested a simpler HIV medication combination in pregnant women to prevent passing the virus to their babies. About 100 women received a two-drug regimen (lopinavir/ritonavir) and 50 received a three-drug regimen (adding zidovudine and lamivudine). The goal was to see if…

This study tested whether having a peer (a friend or community member) talk to African American and Hispanic/Latino men who have sex with men could help them start taking PrEP, a daily pill that prevents HIV. About 98 men who were not on PrEP took part. The goal was to see if thi…

This study tested a toolkit designed to help African American women at risk for HIV get PrEP, a daily pill that prevents HIV. The toolkit was used in two clinics in Mississippi and also addressed intimate partner violence, which can make it harder for women to focus on HIV preven…

This study tested a simple checklist for hospital staff to help people who inject drugs get HIV prevention medicine (PrEP) and addiction treatment. Researchers worked with 60 HIV-negative adults with opioid use disorder at a hospital in Alabama. The goal was to see if this approa…

This study tested different support strategies to help women at high risk for HIV in South Africa keep taking their daily prevention pill (PrEP). 304 female sex workers and young women were given a combination of case management, food vouchers, peer support, or community pick-up …

This study tested a pop-up clinic inside a van to help women who inject drugs and exchange sex get HIV prevention medicine (PrEP), treatment for opioid use disorder, and quick testing for sexually transmitted infections. Fifty women took part in Seattle. The goal was to see if th…

This study looked at how to best give HIV prevention shots (called CAB PrEP) to Black cis and transgender women in the US. Researchers tested different ways to offer the shots in clinics and asked both patients and staff what worked well and what didn't. The goal was to make it e…

This study tested whether giving HIV-negative pregnant women a home HIV test kit for their male partners would increase testing rates compared to just inviting partners to clinic testing. Researchers worked with 200 pregnant women in Malawi, randomly assigning them to either give…

This study tested a training program for people living with HIV to help them become more active in managing their health. The program, led by psychologists, aimed to improve emotional and behavioral involvement in treatment, leading to better quality of life and well-being. 75 pa…

This study looked at whether medical cannabis can reduce nerve pain and inflammation in people with HIV. Thirty-five adults with HIV and neuropathic pain used medical cannabis with different levels of THC and CBD. Researchers tracked changes in pain scores and blood markers of in…

This study looked at whether Tai Chi, a gentle mind-body exercise, can improve quality of life for adults living with both HIV and chronic pain. Researchers enrolled 36 people aged 45 and older to test if the program was practical and liked by participants. The goal was to see if…

This pilot study tested a counseling program called the Friendship Bench for 106 teens aged 13-18 living with HIV who also had depression or anxiety. The program aimed to improve their mood and keep them engaged in HIV care. Researchers measured how well the program worked by loo…

This study tested whether daily cookies made with golden rice and a medicinal plant (piper crocatum) could lower fasting blood sugar and improve quality of life in 102 adults with HIV who also have high blood sugar. Participants ate either the special cookies or plain control coo…

This study worked with 51 healthcare professionals at primary care clinics to find ways to reduce stigma toward people who use drugs. The goal was to improve HIV prevention and care by combining staff education and policy changes. Researchers measured changes in attitudes and int…

This study looked at how pregnancy changes the way the body processes doravirine, an HIV medication. Seven pregnant women living with HIV took a single dose of doravirine during their second and third trimesters and again after giving birth. The goal was to find the right dose fo…

This study tested a digital pill system and a smartphone app to help HIV-negative men who have sex with men and substance use disorder take their daily HIV prevention pill (PrEP) consistently. Forty participants used a special pill that sends a signal when swallowed, and an app t…

This study looked at how HIV and tuberculosis medications are processed in the bodies of pregnant women and their newborns. Researchers measured drug levels in blood and vaginal fluids to understand dosing needs during pregnancy and after childbirth. Over 1,500 women participated…

This study looked at how aging changes certain enzymes (proteins) in the blood and colon. Researchers collected blood and colon tissue samples from 21 adults, both younger (18-50) and older (65-80). They also checked whether the HIV medications tenofovir and emtricitabine affect …

This study looked at whether it's practical to offer rapid HIV testing to men who have sex with men (MSM) in community settings, rather than only at clinics. Researchers worked with teams in France and Canada to test this approach with 357 participants. The goal was to understand…

This study tested a digital, community-led program in rural Appalachia and the Midwest to help people get tested and treated for HIV and hepatitis C, and reduce risks from opioid use. About 511 adults from high-risk counties took part, with half currently using illicit substances…

This study looks at 179 volunteers who received an experimental HIV vaccine about 10 years ago. Researchers want to see if the vaccine's immune effects last that long and how it affects the virus in their bodies. No new treatment is given—this is just an observation to gather lon…

This completed Phase 1 study looked at how the experimental HIV drug VH4524184 is absorbed by the body and how it interacts with food and other common medicines. It involved 126 healthy adults aged 18 to 60. The goal was to gather important information for future use, not to trea…

This study looked back at 30 people with HIV who were treated with CAR T-cell therapy for certain blood cancers like lymphoma or leukemia. Researchers collected standard medical data to see how often side effects occurred and how the immune system changed over time. The goal was …

This early-stage study tested two different versions of a long-acting HIV drug called cabotegravir in 56 healthy adults. The goal was to see how safe the drugs are and how they behave in the body over time. Participants received a single injection and were monitored for side effe…

This study tested a brief video shown in HIV clinic waiting rooms. The goal was to help patients start antiretroviral therapy, stick with their medication, stay in care, and talk to their doctors about safer sex. Over 4,000 patients from clinics serving mostly African American an…

This study looked at how a single dose of THC (the active ingredient in cannabis) changes gene activity and immune signals in the blood of 56 adults—some with HIV and some without. Researchers measured these changes before and after THC infusion to see if the effects differ betwe…

This study looked at how the COVID-19 vaccine works in 75 people aged 55 and older, comparing those with HIV to those without. Researchers measured immune responses and checked for any changes in HIV levels. The goal was to understand if the vaccine is as effective and safe in pe…

This study looked at whether people with HIV prefer getting their long-acting injectable medication at a regular day hospital or a specialized HIV clinic. 90 participants who were already prescribed the shots were randomly assigned to one location. The goal was to measure how acc…

This study looked for undiagnosed HIV in 300 hospital patients who had certain health conditions or behaviors that increase HIV risk. Researchers used a quick finger-prick test and a questionnaire to identify new cases. The goal was to find people who didn't know they had HIV so …

This study followed 248 adults in France who take PrEP (a daily pill to prevent HIV) to see how their sexual behaviors and rates of other sexually transmitted infections (STIs) change over time. Researchers compared people who had been on PrEP for more than a year with those on i…

This study looked at whether community health workers visiting pregnant women at home in rural South Africa could improve health for both mothers and children. About 1,490 women took part, with some areas getting the home-visit program and others not. Researchers tracked things l…

This study tested whether an experimental HIV medicine called ulonivirine (MK-8507) affects heart rhythm. 62 healthy adults received the drug or a placebo, and researchers measured changes in their heart's electrical activity. The goal was to ensure the drug is safe for the heart…

This study followed 200 transgender and non-binary people living with HIV across Europe for 18 months. Researchers collected data from routine blood tests to see how well HIV treatment was working. The goal was to learn more about this group's health needs and help shape future t…

This study looked at how many people held in the Nîmes administrative detention center have HIV, hepatitis B, or hepatitis C. Researchers used rapid tests to get results quickly, since many detainees leave before standard lab results come back. The goal was to find out how common…

This study looked at whether people with HIV who regularly use cannabis could stop for 28 days and whether that would improve their mood, pain, sleep, and HIV-related inflammation. Twenty-five participants were given money rewards to stay cannabis-free, confirmed by urine tests. …

This study looked at how different vaginal infections and bacteria might affect when a baby is born. Researchers followed 603 pregnant women in South Africa, testing for infections and measuring bacteria. The goal was to see which germs are linked to earlier births, but no treatm…

This study looked at how HIV and tuberculosis (TB) medications are processed in the body during pregnancy and after childbirth. Researchers measured drug levels in 205 women to see if standard doses provide enough protection for both mother and baby. The goal was to gather inform…

This completed study looked at how women who inject drugs feel about a long-acting injectable HIV prevention medication called CAB-LA. Researchers wanted to learn what helps or hinders their decision to use it, and how it compares to daily pills. The goal is to design better prog…

This study tested a training program for family medicine doctors in Alabama to help them talk about HIV and STI prevention with teenage girls and young women. 46 doctors completed surveys before and after training to see if the program was practical and well-liked. The goal was t…

This study tested a new rapid HIV test for infants and young children in Zambia to see if it helps more babies start treatment sooner. Researchers enrolled over 1,600 HIV-exposed children up to 17 months old. The goal was to measure how many infected infants began antiretroviral …

This study tested whether involving a person's family and friends can help them stay on methadone treatment for opioid use disorder and take their HIV medication regularly. Researchers adapted a UK program for use in Tanzania and tried it with 20 people receiving methadone and up…

This study tested a method called public deliberation, where community members learn about a topic, hear different viewpoints, and discuss it together to find fair solutions. The goal was to improve how teens from diverse backgrounds give consent to join HIV prevention research, …

This study looked at how regular cannabis use affects brain health and immune function in people with HIV and those without. Researchers compared 276 participants, including both cannabis users and non-users. They measured brain inflammation, structure, and thinking skills to und…

This early study tested whether a single dose of the cancer drug pembrolizumab is safe for people with well-controlled HIV. Researchers wanted to see if the drug could help reveal HIV that may be hiding in the brain. Thirteen adults with HIV took part, and the main goal was to ch…

This study looked at 99 heterosexual men — some living with HIV on effective treatment, others healthy — to compare their quality of life, depression levels, and sexual function. Participants filled out questionnaires about their well-being, mood, and sexual health. The goal was …

This study looked at 460 people with HIV who had cancer to find out which cancers are most common and why some choose to join cancer clinical trials. Researchers collected information on cancer types and offered optional quality-of-life surveys. The goal was to better understand …